Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer
Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if patients with p53 mutated epithelial ovarian
cancer that have been treated with first line treatment (paclitaxel - carboplatin combination
therapy) and that have shown early relapse (within 3 months) or progression during treatment
will benefit from treatment with Wee-1 inhibitor MK-1775 and carboplatin.